Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. - Wikidata - awgldk - TriplyDB

Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.

Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.

http://www.wikidata.org/entity/Q45163892

about

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver A review of the medical treatment of primary sclerosing cholangitis in the 21st century The enteric microbiome in hepatobiliary health and disease Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC)Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies Pathogenesis and clinical spectrum of primary sclerosing cholangitis.Treatment of autoimmune liver disease: current and future therapeutic options.Current status of therapy in autoimmune liver disease Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis.A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.Management of primary sclerosing cholangitis: conventions and controversies Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD Interaction of gut microbiota with bile acid metabolism and its influence on disease states.Clinical features and management of primary sclerosing cholangitis.Hepatobiliary associations with inflammatory bowel disease.Treatment options for primary sclerosing cholangitis.Current management of primary sclerosing cholangitis in pediatric patients.Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis.New treatment strategies for primary sclerosing cholangitis.Pathogenesis of primary sclerosing cholangitis.Primary sclerosing cholangitis: is any treatment worthwhile?Current pharmacotherapy for cholestatic liver disease.Primary sclerosing cholangitis: a review and update on therapeutic developments.Primary sclerosing cholangitis - the Norwegian experience.Primary sclerosing cholangitis: a clinical update.A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis.Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.Emerging treatments for primary sclerosing cholangitis.Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.Role of the microbiota and antibiotics in primary sclerosing cholangitis.The "gut microbiota" hypothesis in primary sclerosing cholangitis.Primary sclerosing cholangitis: diagnostic and management challenges.Cholangitis: Diagnosis, Treatment and Prognosis.Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-cell Receptor-positive Cells and Pathogenesis of Cholestatic Liver Disease.Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma.Searching for Bacterial Biofilm in Recurrent Cholangitis in Primary Sclerosing Cholangitis: A Case Presentation and Introduction of an Unexplored Disease Mechanism.

P2860

Q26766699-1C6F3827-3AD3-4D18-9C4A-EB08B9C18931 Q26771816-7349B3E1-60A5-4B97-B398-1EB86031EC45 Q26777426-A3C5AE9D-9119-4189-885C-D0365B7BC3A7 Q26829300-B41F96FA-110A-4B91-93C6-B0D1D7D34CDB Q27015831-918A1327-E3A1-43BF-B63B-39AC522C66BF Q28076453-6CC6EF21-0DD6-411A-89E7-AFB8D965743D Q31170968-077FDB5E-0029-4C10-8804-0E4EC9C21C51 Q33572623-2DA76EC6-09B8-4025-B3AB-CBB792B8101C Q34342199-39D03E90-AEB8-4AA5-997D-812E75BFD421 Q34408950-E7157FC3-E3ED-4EB7-A883-BBB97741AA62 Q35162765-79AABC24-AA92-42B7-8C6B-BAA248B79C6B Q35778052-09245239-D721-4768-8001-703C250F7EAF Q35962107-7D943FF8-7625-4D06-B1BE-D8A9D30A1774 Q36025017-F65D4FC5-8731-46DF-AD6F-9D201AC9964C Q36204422-88B3FEF7-84E8-44F8-B592-EAF3285D5DAD Q37182946-51F8A69C-46F3-40DB-8666-1959592D3B3E Q37636108-65DE48EB-2510-44A0-8659-05DAEA5D6F03 Q37777156-01AE1316-A1B6-47CD-921D-545095F91315 Q37847138-56F9C7DD-4E34-40FE-B594-823F38F45E23 Q37866339-1B16A69C-21A9-4984-9123-7EC77BFE14D3 Q37892297-DF84A6D2-2AEE-422C-8ECB-EBEC55FF6639 Q37960966-0B318253-8A26-4C4D-A565-73C73A344205 Q37962395-7A01900F-557F-4A0D-A7E2-811907832C5E Q38055205-2637CD49-9957-4E7C-9345-3A031880C2F3 Q38077820-05328B70-8B63-4883-8F7E-7EEB7425DE00 Q38417642-3F47F1AA-E8EE-406B-9157-159DCD8363D8 Q38485235-3ED2B98C-63C1-4ADF-A8F9-3D4496787F2B Q38584285-AAC2175E-2185-4CE0-97C9-FFE644C47001 Q38595151-119E67B5-CB19-499C-AF92-C71CCA5831E0 Q38748384-C295DB2C-B04A-41B3-B964-B72E712CC63A Q38833243-4EA9D618-F5A8-4D5E-B80F-E25AA99E1C8E Q39177947-70B39916-DB36-4196-A05E-82BD3177329B Q42174395-A5062359-1A35-43E5-B878-6086AFDF2E9E Q42330826-F2CA7983-939F-4FF9-9BB6-8FEE62BE5689 Q47112995-B0E04D69-F021-4F6A-AD97-E8AD60B7DB48 Q47137991-B67735E9-4180-4784-AB66-163FD30E3449 Q47162395-AB268B32-0CD7-44F4-A145-15FE4D81B090 Q49896566-3492DEB2-578E-4FA8-AEA8-1CD414702834 Q52972733-697766DC-A3EA-448B-A2B8-6765824D941C Q54982596-3C5FA7E1-CE7D-4B63-8368-FB49AD434B71

P2860

Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.

http://www.wikidata.org/entity/Q45163892

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Metronidazole and ursodeoxycho ...... ized placebo-controlled trial.

@en

Metronidazole and ursodeoxycho ...... ized placebo-controlled trial.

@nl

type

label

Metronidazole and ursodeoxycho ...... ized placebo-controlled trial.

@en

Metronidazole and ursodeoxycho ...... ized placebo-controlled trial.

@nl

prefLabel

Metronidazole and ursodeoxycho ...... ized placebo-controlled trial.

@en

Metronidazole and ursodeoxycho ...... ized placebo-controlled trial.

@nl

P1433

Q45163892-BA6D0916-F925-4383-B543-717A59D17641

P1476

Q45163892-AB6E1744-943D-461E-B4F8-F642DC0EC5D8

P2093

Q45163892-1F31C9D4-E73B-41D6-B810-85040EC10B3E

Q45163892-2265B076-DDD2-4FAD-BDC7-0843B8DC4207

Q45163892-262083B5-2A32-4FBD-879E-23A5930BFDE6

Q45163892-5B15149C-E824-4194-B898-646638D89008

Q45163892-E21A859C-3F3A-425B-B884-781A32C2E9EB

Q45163892-E851EED9-D617-4599-94A2-3BE838390D4C

P2860

Q45163892-08B66987-45F5-48D8-8622-DCFB51DA0E97

Q45163892-2E467B54-D83F-4A4F-856E-B89BE7E1EE14

Q45163892-44A46888-4A1A-44B7-A019-24ABA9F1A364

Q45163892-70BFB889-C2EE-4E2E-AA84-559F589688E8

Q45163892-8B0B74C9-A173-4605-ABEE-3B486DBD3456

Q45163892-8F92B114-4496-4D32-BFAC-A4E302F4B405

Q45163892-B50A711F-7888-4F72-80DE-EFB80F664298

Q45163892-B71E46F4-A7FA-4A45-AE8A-072C06689390

Q45163892-BAC66A6D-846F-49B9-8E3E-B71F79E1858C

Q45163892-BB77B822-46CE-4958-949A-E0D717EF6E05

P304

Q45163892-12176DB2-0EFD-4AEA-B7CA-9D6081FCD430

P31

Q45163892-322C0F62-32D3-469C-9CEC-F45F554226DA

P356

Q45163892-B884179E-8ACF-4F9F-A03B-2EA54673F604

P407

Q45163892-3252BB6F-0F26-4350-84D9-093E35027733

P433

Q45163892-CA3C1C1B-B171-491A-A4E4-870F6D749F9F

P478

Q45163892-AE4274D6-03DA-41EE-81DB-483545F866B6

P50

Q45163892-519C9585-B550-4F38-8563-4FC4D08E01AE

P577

Q45163892-6AAA7BF2-324C-4712-8230-BCC652BBA628

P5875

Q45163892-554E8A17-5F9B-46A6-BFE6-054E2BEF7CFF

P698

Q45163892-ACD1A1A7-79E0-4BF5-AD66-488AC49DBDC6

P921

Q45163892-0ED741EC-75F6-4B62-B419-D90C545B7513

Q45163892-C28800FB-DCB4-4541-89D6-82302D8924AE

P356

P1433

P1476

Metronidazole and ursodeoxycho ...... ized placebo-controlled trial.

@en

P2093

Anna-Liisa Karvonen

http://www.w3.org/2001/XMLSchema#string

Hannu Nuutinen

http://www.w3.org/2001/XMLSchema#string

Heimo Nurmi

http://www.w3.org/2001/XMLSchema#string

Matti Taavitsainen

http://www.w3.org/2001/XMLSchema#string

Pekka Pikkarainen

http://www.w3.org/2001/XMLSchema#string

Päivi Kärkkäinen

http://www.w3.org/2001/XMLSchema#string

P2860

HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations

Primary sclerosing cholangitis.

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population.

Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.

Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?

Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.

Effects of antimicrobial agents on spontaneous and endotoxin-induced cytokine release of human peripheral blood mononuclear cells.

Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy.

P304

1379-1386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.20457

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Martti Färkkilä

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8161077

http://www.w3.org/2001/XMLSchema#string

P698

15565569

http://www.w3.org/2001/XMLSchema#string

P921